David Spetzler, President and Chief Scientific Officer at Caris Life Sciences, shared a post by Caris Life Sciences, adding:
“We’re proud to share our new Caris Life Sciences study results validating MI Cancer Seek®, a comprehensive molecular profiling assay that delivers reliable, high-quality insights without compromising tissue preservation. Some key takeaways include:
- Detects multiple clinically significant variant types
- Supports eight companion diagnostic (CDx) claims in high burden areas
- Matches FDA-approval assays with 97-100% agreement
- Enables simultaneous RNA and DNA extraction from minimal tissue input.”
Quoting Caris Life Sciences‘s post:
“A recently published study in Oncotarget validates the analytical and clinical performance of MI Cancer Seek®. It demonstrates that MI Cancer Seek reliably detects multiple variant types of high clinical significance, and that its approved medical uses follow strict laboratory standards.
“MI Cancer Seek provides a comprehensive molecular blueprint that saves tissue without compromising results. The study results underscore our commitment to ongoing scientific integrity and validation,” said David Spetzler, President of Caris.
More posts featuring David Spetzler.